

MAR. 10. 2004 6:17PM

SCHLUMBERGER

NO. 321 P. 1

**RECEIVED  
CENTRAL FAX CENTER**

MAR 10 2004

Sugar Land Product Center  
200 Gillingham Lane  
Sugar Land, Texas 77478  
(281) 285-7325  
(281) 285-4232 Fax

**OFFICIAL**

**Schlumberger**

## Fax message

---

To	Examiner D. Vargas	Location	USPTO
cc		Fax	(703) 872-9306
From	Kevin McEnaney <i>KPM</i>	Date	March 10, 2004
Subject	Serial No: 10/051,479 Our File: 24.0846	Pages (inc)	17

---

**PATENT**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**RECEIVED**  
**CENTRAL FAX CENTER**

MAR 10 2004

**OFFICIAL**

In re Application of:  
K. Ganesan

Serial No.: 10/051,479

Filed: January 18, 2002

For: Nuclear Magnetic Resonance Imaging  
Using Phase Encoding

Group Art Unit: 2859

Examiner: D. Vargas

Atty. Dkt. No.: 24.0846

I hereby certify that this correspondence is being facsimile  
transmitted to the United States Patent and Trademark  
Office, Fax No. (703) 872-9306.

  
Kevin McEnaney

March 10, 2004  
Date

**SUPPLEMENTAL AMENDMENT AFTER FINAL**

Assistant Commissioner for Patents  
Washington, D. C. 20231

Dear Madam:

In response to the Final Office Action dated November 28, 2003, please consider the following comments

**Introductory Comments**

In the first Office Action, the independent claims 1, 36, 51, 58, 59, 60, 66, 69, and 72, along with certain dependent claims have been rejected under section 102 as being anticipated by Sun. Certain other dependent claims have been rejected under section 103 based on Sun in view of Ganesan. Applicant's filed a Response and Amendment offering amendments and comments that distinguished Sun from Applicants' claimed subject matter. In the final Office Action the rejection of all claims was maintained and a final office action has issued. Applicant's provided additional distinguishing comments in its second Response. A telephone interview was then conducted on March 10, 2004 between Kevin McEnaney and Examiner Vargas. The amendments herein to claims 1, 36, 51, 58, 59, 60, 66, 69, and 72, adopt suggestions made by the Examiner. Claims 1-62, 64-67, 69-70, and 72-76 remain under consideration.